Indian-based CRO-CDMO Sai Life Sciences opened a new High Potency API (HPAPI) manufacturing facility in Bidar, India, the company announced this week.
The new 16,000-square-foot site expands its cGMP API Manufacturing campus and is a part of the company’s Sai Nxt initiative — a $120 million investment commitment to grow its capacity and operations.
Specifically, the new site has the capacity to handle highly potent molecules of less than 1 μg/m3 containment, a dedicated sampling and dispensing area with three independent streams to handle commercial scale batches, a powder processing and packing area with isolators, and a dedicated isolator train for quality control testing.
Last year, the company opened its HPAPI Development facility at its Hyderabad facility. Established in 1999, Sai Life Sciences currently works with over 200 companies worldwide and has facilities in India, the UK, and the United States.
